{
    "info": {
        "nct_id": "NCT05526248",
        "official_title": "A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer",
        "inclusion_criteria": "* Male of ≥ 18 years of age.\n* Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate.\n* Prior treatment with primary radical prostatectomy or definitive RT for localized prostate cancer\n* Patients must have PSA ≥0.2 ng/mL after ART or SRT post-RP or after RP in participants who are unfit for ART or SRT, OR PSA ≥2 ng/mL above the nadir after primary RT only. (RP, radical prostatectomy; ART, adjuvant radiotherapy; SRT, salvage radiotherapy; RT primary radiotherapy)\n* The presence of < 5 asymptomatic metastatic lesions on conventional or PSMA-PET based imaging methods permitted. Lesions that need treatment with any opioid based analgetic are considered symptomatic\n* PSADT ≤ 20 months calculated per PCWG3 + RECIST 1.1 per Scher et al. (Scher et al. 2016) and MSKCC nomogram.\n* Eastern Cooperative Oncology Group ECOG (PS) of 0 - 1.\n* Serum testosterone >150 ng/dl.\n* Patients must have adequate organ function within 4 weeks before the first dose of study intervention.\n* More than 30 days (or 5 half-lives) (whichever is longer) since prior participation in another clinical trial with an investigational medicinal product.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with ADT of up to 6 months for localized disease is permitted but not if during the prior 6 months before first dose of study intervention. Plan to initiate ADT during the trial period is not allowed.\n* Radiation therapy or major surgery within 4 weeks of screening.\n* Systemic glucocorticoids within 3 months prior to the first dose or study intervention was expected to require systemic glucocorticoids during the study period\n* Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)\n* Uncontrolled hypertension\n* A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study intervention.\n* Prior history of a clinically significant malignancy with the exception of basal cell, squamous cell carcinoma of the skin, and superficial bladder cancer.\n* Prior treatment with:\n\n  * Second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, darolutamide other investigational AR inhibitors\n  * or Cytochrome P17 enzyme inhibitor such as abiraterone acetate as antineoplastic treatment for prostate cancer\n* Prior history of gynecomastia\n* Use of herbal products that may have had hormonal anti-prostate cancer activity or were known to decrease PSA levels (e.g., saw palmetto) within 4 weeks before the first dose of study intervention",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group ECOG (PS) of 0 - 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group ECOG (PS) of 0 - 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum testosterone >150 ng/dl.",
            "criterions": [
                {
                    "exact_snippets": "Serum testosterone >150 ng/dl",
                    "criterion": "serum testosterone",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "ng/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male of ≥ 18 years of age.",
            "criterions": [
                {
                    "exact_snippets": "Male",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have PSA ≥0.2 ng/mL after ART or SRT post-RP or after RP in participants who are unfit for ART or SRT, OR PSA ≥2 ng/mL above the nadir after primary RT only. (RP, radical prostatectomy; ART, adjuvant radiotherapy; SRT, salvage radiotherapy; RT primary radiotherapy)",
            "criterions": [
                {
                    "exact_snippets": "PSA ≥0.2 ng/mL after ART or SRT post-RP or after RP in participants who are unfit for ART or SRT",
                    "criterion": "prostate-specific antigen (PSA) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.2,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "after ART",
                                "after SRT post-RP",
                                "after RP in participants who are unfit for ART or SRT"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "PSA ≥2 ng/mL above the nadir after primary RT only",
                    "criterion": "prostate-specific antigen (PSA) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ng/mL above the nadir"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after primary RT only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* More than 30 days (or 5 half-lives) (whichever is longer) since prior participation in another clinical trial with an investigational medicinal product.",
            "criterions": [
                {
                    "exact_snippets": "More than 30 days (or 5 half-lives) (whichever is longer) since prior participation in another clinical trial with an investigational medicinal product.",
                    "criterion": "prior participation in another clinical trial with an investigational medicinal product",
                    "requirements": [
                        {
                            "requirement_type": "time since prior participation",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The presence of < 5 asymptomatic metastatic lesions on conventional or PSMA-PET based imaging methods permitted. Lesions that need treatment with any opioid based analgetic are considered symptomatic",
            "criterions": [
                {
                    "exact_snippets": "The presence of < 5 asymptomatic metastatic lesions on conventional or PSMA-PET based imaging methods permitted.",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "lesions"
                            }
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Lesions that need treatment with any opioid based analgetic are considered symptomatic",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "opioid based analgetic"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSADT ≤ 20 months calculated per PCWG3 + RECIST 1.1 per Scher et al. (Scher et al. 2016) and MSKCC nomogram.",
            "criterions": [
                {
                    "exact_snippets": "PSADT ≤ 20 months",
                    "criterion": "prostate-specific antigen doubling time (PSADT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 20,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated per PCWG3 + RECIST 1.1 per Scher et al. (Scher et al. 2016) and MSKCC nomogram",
                    "criterion": "PSADT calculation method",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": [
                                "PCWG3",
                                "RECIST 1.1 per Scher et al. (2016)",
                                "MSKCC nomogram"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with primary radical prostatectomy or definitive RT for localized prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with primary radical prostatectomy",
                    "criterion": "primary radical prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "definitive RT for localized prostate cancer",
                    "criterion": "definitive radiotherapy (RT) for localized prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have adequate organ function within 4 weeks before the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function within 4 weeks before the first dose of study intervention",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Radiation therapy or major surgery within 4 weeks of screening.",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy ... within 4 weeks of screening",
                    "criterion": "radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "major surgery within 4 weeks of screening",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of gynecomastia",
            "criterions": [
                {
                    "exact_snippets": "Prior history of gynecomastia",
                    "criterion": "gynecomastia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with:",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with:",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of a clinically significant malignancy with the exception of basal cell, squamous cell carcinoma of the skin, and superficial bladder cancer.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of a clinically significant malignancy with the exception of basal cell, squamous cell carcinoma of the skin, and superficial bladder cancer.",
                    "criterion": "prior history of clinically significant malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin",
                                "superficial bladder cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* or Cytochrome P17 enzyme inhibitor such as abiraterone acetate as antineoplastic treatment for prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Cytochrome P17 enzyme inhibitor such as abiraterone acetate as antineoplastic treatment for prostate cancer",
                    "criterion": "antineoplastic treatment for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "Cytochrome P17 enzyme inhibitor (e.g., abiraterone acetate)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, darolutamide other investigational AR inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Second-generation androgen receptor (AR) inhibitors such as enzalutamide, apalutamide, darolutamide other investigational AR inhibitors",
                    "criterion": "second-generation androgen receptor (AR) inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug_names",
                            "expected_value": [
                                "enzalutamide",
                                "apalutamide",
                                "darolutamide",
                                "other investigational AR inhibitors"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of herbal products that may have had hormonal anti-prostate cancer activity or were known to decrease PSA levels (e.g., saw palmetto) within 4 weeks before the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Use of herbal products that may have had hormonal anti-prostate cancer activity ... within 4 weeks before the first dose of study intervention",
                    "criterion": "use of herbal products with hormonal anti-prostate cancer activity",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose of study intervention"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of herbal products that ... were known to decrease PSA levels (e.g., saw palmetto) within 4 weeks before the first dose of study intervention",
                    "criterion": "use of herbal products known to decrease PSA levels",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose of study intervention"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)",
            "criterions": [
                {
                    "exact_snippets": "stroke ... within 6 months before randomization",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within 6 months before randomization",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe/unstable angina pectoris ... within 6 months before randomization",
                    "criterion": "severe/unstable angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary/peripheral artery bypass graft ... within 6 months before randomization",
                    "criterion": "coronary artery bypass graft or peripheral artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure (New York Heart Association Class III or IV) ... within 6 months before randomization",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        },
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with ADT of up to 6 months for localized disease is permitted but not if during the prior 6 months before first dose of study intervention. Plan to initiate ADT during the trial period is not allowed.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with ADT of up to 6 months for localized disease is permitted",
                    "criterion": "prior ADT treatment duration for localized disease",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not if during the prior 6 months before first dose of study intervention",
                    "criterion": "prior ADT treatment timing",
                    "requirements": [
                        {
                            "requirement_type": "time since last ADT",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Plan to initiate ADT during the trial period is not allowed",
                    "criterion": "planned ADT initiation during trial",
                    "requirements": [
                        {
                            "requirement_type": "planned initiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic glucocorticoids within 3 months prior to the first dose or study intervention was expected to require systemic glucocorticoids during the study period",
            "criterions": [
                {
                    "exact_snippets": "Systemic glucocorticoids within 3 months prior to the first dose",
                    "criterion": "systemic glucocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to first dose"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "study intervention was expected to require systemic glucocorticoids during the study period",
                    "criterion": "expected need for systemic glucocorticoids",
                    "requirements": [
                        {
                            "requirement_type": "expected use during study period",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "A gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study intervention",
                    "criterion": "gastrointestinal disorder or procedure",
                    "requirements": [
                        {
                            "requirement_type": "expected interference with absorption of study intervention",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}